Financial Performance - Operating revenue for the first quarter of 2023 reached CNY 59.37 million, representing a year-on-year growth of 57.49% from CNY 37.69 million[10] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 11.22 million, a significant increase of 100.74% compared to CNY 5.59 million in the same period last year[10] - The gross profit margin improved due to an increase in the sales proportion of hearing aids, leading to a 132.12% increase in operating profit to CNY 13.25 million[17] - Total revenue for Q1 2023 reached ¥59,366,785.38, a significant increase from ¥37,694,584.15 in Q1 2022, representing a growth of approximately 57.5%[49] - The net profit for Q1 2023 reached 12,005,443.63 yuan, compared to 5,365,879.18 yuan in Q1 2022, indicating a year-over-year increase of about 123.5%[51] - The total profit for Q1 2023 was 13,258,282.80 yuan, up from 5,948,961.20 yuan in Q1 2022, reflecting an increase of approximately 122.5%[51] Cash Flow - The company's cash flow from operating activities for the first quarter was CNY 6.08 million, down 16.38% from CNY 7.27 million in the previous year[10] - Cash inflow from operating activities for Q1 2023 was CNY 54,310,200.09, an increase of 17.5% compared to CNY 46,223,409.90 in Q1 2022[56] - Net cash flow from operating activities for Q1 2023 was CNY 6,081,517.69, a decrease of 16.4% from CNY 7,272,807.75 in Q1 2022[56] - Cash inflow from investment activities in Q1 2023 was CNY 105,611,289.58, up 77% from CNY 59,722,149.17 in Q1 2022[57] - Net cash flow from investment activities for Q1 2023 was CNY 13,562,348.45, a significant recovery from a negative CNY 34,038,114.12 in Q1 2022[57] Assets and Liabilities - Total assets as of March 31, 2023, amounted to CNY 449.90 million, an increase of 7.72% compared to CNY 417.66 million at the end of 2022[10] - The company's asset-liability ratio (consolidated) increased to 17.34% from 12.67% year-on-year, indicating a rise in leverage[10] - Total liabilities rose to ¥78,011,395.98 in Q1 2023, up from ¥52,905,039.28 in Q4 2022, indicating an increase of approximately 47.8%[43] - Current liabilities totaled ¥72,255,980.83 as of March 31, 2023, compared to ¥47,506,643.47 at the end of 2022, marking a rise of around 51.9%[43] - Non-current assets amounted to ¥259,504,061.89 as of March 31, 2023, up from ¥230,673,684.25 at the end of 2022, showing an increase of about 12.5%[43] Shareholder Information - The total number of unrestricted shares is 27,667,955, representing 56.15% of the total share capital[23] - The total number of restricted shares is 21,607,045, representing 43.85% of the total share capital[23] - The largest shareholder, Wang Min, holds 12,703,057 shares, accounting for 25.78% of the total shares[26] - The second-largest shareholder, Wang Fang, holds 9,526,818 shares, accounting for 19.33% of the total shares[26] - The company has a total share capital of 49,275,000 shares[23] Research and Development - Research and development expenses for the quarter were CNY 5.09 million, reflecting a 67.36% increase, indicating a continued commitment to R&D investment[16] - Research and development expenses for Q1 2023 amounted to 5,091,791.65 yuan, up from 3,042,481.56 yuan in Q1 2022, reflecting a growth of approximately 67.1%[50] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[49] - The company is actively pursuing strategies for market expansion and new product development as part of its growth initiatives[36] Legal and Compliance - The company has not reported any significant legal disputes or external guarantees during the reporting period[29] - The company has committed to ensuring accurate information disclosure and has stated that there are no false records or misleading statements in its public disclosures[37]
锦好医疗(872925) - 2023 Q1 - 季度财报